| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antibodies, Monoclonal | 64 | 2026 | 875 | 4.900 |
Why?
|
| HIV Antibodies | 36 | 2018 | 145 | 4.310 |
Why?
|
| HIV-1 | 42 | 2018 | 703 | 3.530 |
Why?
|
| Immunoglobulin A | 10 | 2026 | 102 | 2.980 |
Why?
|
| Antibodies, Neutralizing | 10 | 2026 | 217 | 1.970 |
Why?
|
| HIV Envelope Protein gp120 | 25 | 2018 | 130 | 1.950 |
Why?
|
| HIV Infections | 24 | 2018 | 953 | 1.790 |
Why?
|
| Antibodies, Bacterial | 17 | 2026 | 181 | 1.790 |
Why?
|
| Epitopes | 24 | 2026 | 291 | 1.740 |
Why?
|
| Lyme Disease | 9 | 2026 | 123 | 1.660 |
Why?
|
| Enterotoxigenic Escherichia coli | 7 | 2023 | 22 | 1.620 |
Why?
|
| Borrelia burgdorferi | 8 | 2026 | 93 | 1.510 |
Why?
|
| Single-Domain Antibodies | 4 | 2026 | 21 | 1.490 |
Why?
|
| Immunoglobulin G | 22 | 2024 | 463 | 1.480 |
Why?
|
| Immunoglobulin Fc Fragments | 3 | 2026 | 48 | 1.340 |
Why?
|
| Immunoglobulin A, Secretory | 6 | 2023 | 22 | 1.220 |
Why?
|
| Bacterial Outer Membrane Proteins | 10 | 2026 | 127 | 1.210 |
Why?
|
| Antibody Specificity | 8 | 2020 | 102 | 1.180 |
Why?
|
| Neutralization Tests | 30 | 2018 | 125 | 1.130 |
Why?
|
| HIV Envelope Protein gp41 | 9 | 2016 | 27 | 0.960 |
Why?
|
| Receptors, Fc | 4 | 2024 | 25 | 0.890 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2026 | 500 | 0.880 |
Why?
|
| Lipoproteins | 6 | 2026 | 85 | 0.760 |
Why?
|
| Antibodies, Bispecific | 2 | 2016 | 33 | 0.730 |
Why?
|
| Pemphigus | 4 | 2016 | 14 | 0.720 |
Why?
|
| Autoantibodies | 4 | 2016 | 184 | 0.710 |
Why?
|
| Escherichia coli Infections | 6 | 2023 | 87 | 0.700 |
Why?
|
| CD4 Antigens | 14 | 2013 | 149 | 0.650 |
Why?
|
| Lyme Disease Vaccines | 6 | 2026 | 10 | 0.640 |
Why?
|
| Animals | 56 | 2026 | 21264 | 0.630 |
Why?
|
| Mice | 34 | 2026 | 11071 | 0.630 |
Why?
|
| Antigens, Surface | 8 | 2026 | 199 | 0.620 |
Why?
|
| Peptide Fragments | 7 | 2009 | 415 | 0.600 |
Why?
|
| Bacterial Vaccines | 6 | 2026 | 79 | 0.600 |
Why?
|
| Desmoglein 3 | 3 | 2016 | 6 | 0.580 |
Why?
|
| HIV | 4 | 2013 | 67 | 0.580 |
Why?
|
| Immunization, Passive | 12 | 2023 | 96 | 0.570 |
Why?
|
| Antigens, Bacterial | 5 | 2026 | 200 | 0.560 |
Why?
|
| Immunoglobulin Fab Fragments | 7 | 2025 | 33 | 0.530 |
Why?
|
| Humans | 84 | 2026 | 64768 | 0.520 |
Why?
|
| Epitopes, B-Lymphocyte | 4 | 2025 | 18 | 0.520 |
Why?
|
| Caulobacter crescentus | 3 | 2013 | 36 | 0.510 |
Why?
|
| Immunoglobulin Isotypes | 3 | 2012 | 24 | 0.500 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2018 | 249 | 0.490 |
Why?
|
| Single-Chain Antibodies | 1 | 2016 | 5 | 0.490 |
Why?
|
| Antibodies, Viral | 6 | 2026 | 325 | 0.490 |
Why?
|
| Anti-HIV Agents | 4 | 2013 | 138 | 0.480 |
Why?
|
| Escherichia coli Vaccines | 3 | 2021 | 11 | 0.460 |
Why?
|
| Immunoglobulin Variable Region | 7 | 2007 | 34 | 0.460 |
Why?
|
| Spike Glycoprotein, Coronavirus | 4 | 2026 | 114 | 0.460 |
Why?
|
| Neutrophils | 3 | 2025 | 387 | 0.440 |
Why?
|
| Binding Sites, Antibody | 4 | 2012 | 21 | 0.430 |
Why?
|
| Antigens, CD | 5 | 2016 | 342 | 0.420 |
Why?
|
| Ticks | 3 | 2023 | 35 | 0.420 |
Why?
|
| Immunoglobulin Constant Regions | 1 | 2012 | 8 | 0.390 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 6 | 2023 | 449 | 0.380 |
Why?
|
| Milk | 2 | 2013 | 47 | 0.380 |
Why?
|
| Simian Immunodeficiency Virus | 8 | 2011 | 84 | 0.380 |
Why?
|
| Epitope Mapping | 7 | 2025 | 52 | 0.360 |
Why?
|
| AIDS Vaccines | 6 | 2011 | 72 | 0.350 |
Why?
|
| Diarrhea | 3 | 2021 | 73 | 0.350 |
Why?
|
| Tuberculosis | 2 | 2025 | 305 | 0.340 |
Why?
|
| Virion | 5 | 2016 | 122 | 0.340 |
Why?
|
| Membrane Glycoproteins | 5 | 2013 | 661 | 0.330 |
Why?
|
| Mycobacterium tuberculosis | 2 | 2025 | 417 | 0.320 |
Why?
|
| Cell Line | 13 | 2021 | 2019 | 0.310 |
Why?
|
| Immunoglobulins | 1 | 2010 | 74 | 0.310 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 7 | 2011 | 62 | 0.290 |
Why?
|
| Camelids, New World | 2 | 2026 | 10 | 0.280 |
Why?
|
| Protein Engineering | 2 | 2026 | 85 | 0.280 |
Why?
|
| Malaria | 5 | 1990 | 156 | 0.280 |
Why?
|
| Immunoglobulin Class Switching | 2 | 2007 | 82 | 0.250 |
Why?
|
| Adhesins, Bacterial | 1 | 2025 | 10 | 0.230 |
Why?
|
| Protein Multimerization | 2 | 2020 | 181 | 0.230 |
Why?
|
| Gene Products, env | 2 | 2003 | 18 | 0.220 |
Why?
|
| Glucuronic Acid | 1 | 2004 | 20 | 0.220 |
Why?
|
| Hexuronic Acids | 1 | 2004 | 23 | 0.220 |
Why?
|
| Antibody Affinity | 3 | 2021 | 18 | 0.220 |
Why?
|
| Immunity, Cellular | 6 | 2010 | 170 | 0.210 |
Why?
|
| Pseudomonas Infections | 1 | 2004 | 73 | 0.210 |
Why?
|
| Glycosylation | 5 | 2021 | 138 | 0.210 |
Why?
|
| Immunodominant Epitopes | 2 | 2008 | 57 | 0.210 |
Why?
|
| Virus Replication | 1 | 2005 | 321 | 0.210 |
Why?
|
| Cell Membrane | 3 | 2002 | 504 | 0.200 |
Why?
|
| HIV Antigens | 1 | 2003 | 18 | 0.200 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2004 | 132 | 0.200 |
Why?
|
| Cricetulus | 3 | 2019 | 103 | 0.200 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 3 | 2016 | 29 | 0.190 |
Why?
|
| Protein Binding | 4 | 2025 | 1638 | 0.190 |
Why?
|
| CHO Cells | 3 | 2019 | 192 | 0.190 |
Why?
|
| Borrelia burgdorferi Group | 1 | 2022 | 30 | 0.190 |
Why?
|
| Immunoglobulin Heavy Chains | 4 | 1998 | 47 | 0.190 |
Why?
|
| Mice, SCID | 4 | 2018 | 518 | 0.180 |
Why?
|
| Immunity, Humoral | 2 | 2014 | 39 | 0.180 |
Why?
|
| Recombinant Proteins | 4 | 2011 | 710 | 0.180 |
Why?
|
| Chemokine CCL3 | 2 | 2013 | 8 | 0.180 |
Why?
|
| Crystallography, X-Ray | 5 | 2025 | 419 | 0.180 |
Why?
|
| Plasmodium | 4 | 1990 | 33 | 0.180 |
Why?
|
| Cancer Vaccines | 1 | 2002 | 51 | 0.180 |
Why?
|
| Prostate-Specific Antigen | 1 | 2002 | 84 | 0.170 |
Why?
|
| Chlamydia trachomatis | 1 | 2021 | 60 | 0.170 |
Why?
|
| Cervix Uteri | 1 | 2021 | 58 | 0.170 |
Why?
|
| Cross Reactions | 7 | 2020 | 139 | 0.170 |
Why?
|
| Molecular Sequence Data | 9 | 2011 | 1979 | 0.170 |
Why?
|
| Chlamydia Infections | 1 | 2021 | 79 | 0.170 |
Why?
|
| Herpesvirus 4, Human | 2 | 1999 | 198 | 0.170 |
Why?
|
| Macaca mulatta | 9 | 2021 | 260 | 0.160 |
Why?
|
| Chromatography, Affinity | 1 | 2020 | 51 | 0.160 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2020 | 45 | 0.160 |
Why?
|
| Escherichia coli Proteins | 2 | 2021 | 277 | 0.160 |
Why?
|
| Cricetinae | 2 | 2013 | 362 | 0.150 |
Why?
|
| Keratinocytes | 3 | 2016 | 71 | 0.150 |
Why?
|
| Administration, Oral | 6 | 2023 | 369 | 0.150 |
Why?
|
| T-Lymphocytes | 6 | 1993 | 1004 | 0.150 |
Why?
|
| Gastrointestinal Tract | 1 | 2020 | 189 | 0.140 |
Why?
|
| Antigen-Antibody Reactions | 3 | 2010 | 13 | 0.140 |
Why?
|
| Betacoronavirus | 1 | 2020 | 181 | 0.140 |
Why?
|
| Disease Models, Animal | 8 | 2021 | 2274 | 0.140 |
Why?
|
| Amino Acid Sequence | 8 | 2009 | 1589 | 0.140 |
Why?
|
| Animals, Genetically Modified | 1 | 2018 | 310 | 0.140 |
Why?
|
| Head and Neck Neoplasms | 3 | 2005 | 164 | 0.130 |
Why?
|
| Viral Envelope Proteins | 2 | 2016 | 101 | 0.130 |
Why?
|
| Mice, Inbred NOD | 1 | 2018 | 526 | 0.130 |
Why?
|
| Models, Molecular | 7 | 2023 | 1160 | 0.130 |
Why?
|
| Polymers | 1 | 2020 | 331 | 0.130 |
Why?
|
| Prostatic Neoplasms | 1 | 2002 | 493 | 0.130 |
Why?
|
| Cells, Cultured | 3 | 2016 | 2187 | 0.130 |
Why?
|
| Structure-Activity Relationship | 3 | 2010 | 354 | 0.130 |
Why?
|
| Female | 20 | 2024 | 33804 | 0.130 |
Why?
|
| Acquired Immunodeficiency Syndrome | 5 | 2001 | 129 | 0.130 |
Why?
|
| Exfoliatins | 1 | 2016 | 1 | 0.120 |
Why?
|
| Antibody Formation | 2 | 2016 | 110 | 0.120 |
Why?
|
| Genes, Immunoglobulin | 4 | 2003 | 33 | 0.120 |
Why?
|
| Complementarity Determining Regions | 2 | 2014 | 33 | 0.120 |
Why?
|
| CD4 Lymphocyte Count | 6 | 2006 | 92 | 0.120 |
Why?
|
| Hemorrhagic Fever, Ebola | 1 | 2016 | 29 | 0.120 |
Why?
|
| Tumor Cells, Cultured | 5 | 2003 | 426 | 0.120 |
Why?
|
| Ebolavirus | 1 | 2016 | 39 | 0.120 |
Why?
|
| Transplantation, Heterologous | 2 | 1992 | 240 | 0.110 |
Why?
|
| Base Sequence | 5 | 2006 | 1329 | 0.110 |
Why?
|
| Microscopy, Fluorescence | 1 | 2016 | 401 | 0.110 |
Why?
|
| Mice, Transgenic | 2 | 2021 | 1286 | 0.110 |
Why?
|
| Animals, Newborn | 6 | 2006 | 239 | 0.110 |
Why?
|
| Nanoparticles | 1 | 2020 | 544 | 0.110 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2001 | 246 | 0.100 |
Why?
|
| Hybridomas | 2 | 2004 | 63 | 0.100 |
Why?
|
| Genetic Engineering | 2 | 2013 | 113 | 0.100 |
Why?
|
| Phagocytosis | 2 | 2006 | 257 | 0.100 |
Why?
|
| Sequence Homology, Nucleic Acid | 2 | 2007 | 111 | 0.100 |
Why?
|
| Infectious Disease Transmission, Vertical | 5 | 2003 | 80 | 0.100 |
Why?
|
| Antibodies, Protozoan | 2 | 1990 | 56 | 0.100 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 1992 | 138 | 0.100 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2006 | 33 | 0.100 |
Why?
|
| Skin | 1 | 2016 | 416 | 0.100 |
Why?
|
| Lymphocyte Transfusion | 1 | 1992 | 37 | 0.100 |
Why?
|
| B-Lymphocytes | 3 | 2006 | 563 | 0.090 |
Why?
|
| CD40 Antigens | 2 | 2005 | 59 | 0.090 |
Why?
|
| Virus Internalization | 1 | 2013 | 91 | 0.090 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 1992 | 74 | 0.090 |
Why?
|
| Immunity, Innate | 3 | 2025 | 818 | 0.090 |
Why?
|
| Plasmids | 1 | 2013 | 294 | 0.090 |
Why?
|
| Protein Structure, Tertiary | 3 | 2008 | 676 | 0.090 |
Why?
|
| Mammals | 2 | 2023 | 221 | 0.090 |
Why?
|
| Immunotherapy | 2 | 2021 | 270 | 0.080 |
Why?
|
| Caco-2 Cells | 2 | 2021 | 67 | 0.080 |
Why?
|
| Male | 13 | 2024 | 30840 | 0.080 |
Why?
|
| Gene Expression | 2 | 2013 | 849 | 0.080 |
Why?
|
| Cloning, Molecular | 2 | 2003 | 384 | 0.080 |
Why?
|
| Gene Rearrangement, B-Lymphocyte | 1 | 2010 | 13 | 0.080 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2005 | 260 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 3 | 2025 | 3467 | 0.080 |
Why?
|
| Organ Specificity | 1 | 2010 | 198 | 0.080 |
Why?
|
| Macrophage Activation | 1 | 1989 | 115 | 0.070 |
Why?
|
| Leukocytes | 1 | 1989 | 105 | 0.070 |
Why?
|
| Immune Evasion | 1 | 2009 | 71 | 0.070 |
Why?
|
| Amino Acid Substitution | 3 | 2021 | 237 | 0.070 |
Why?
|
| Sequence Analysis, DNA | 2 | 2021 | 414 | 0.070 |
Why?
|
| Macaca fascicularis | 2 | 2021 | 48 | 0.070 |
Why?
|
| Protein Conformation | 3 | 2009 | 790 | 0.070 |
Why?
|
| Drug Delivery Systems | 1 | 2011 | 333 | 0.070 |
Why?
|
| Mice, Inbred BALB C | 6 | 2006 | 869 | 0.070 |
Why?
|
| Species Specificity | 3 | 2004 | 339 | 0.070 |
Why?
|
| Acute Disease | 2 | 2004 | 663 | 0.070 |
Why?
|
| Blotting, Western | 4 | 2006 | 610 | 0.070 |
Why?
|
| Sequence Alignment | 2 | 2008 | 300 | 0.060 |
Why?
|
| Binding Sites | 5 | 2009 | 920 | 0.060 |
Why?
|
| Mutagenesis, Site-Directed | 2 | 2007 | 251 | 0.060 |
Why?
|
| Acetylglucosamine | 1 | 2006 | 11 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2024 | 2690 | 0.060 |
Why?
|
| Immunity, Mucosal | 3 | 2002 | 53 | 0.060 |
Why?
|
| HeLa Cells | 1 | 2007 | 541 | 0.060 |
Why?
|
| Immunologic Factors | 1 | 2006 | 106 | 0.060 |
Why?
|
| NIH 3T3 Cells | 1 | 2005 | 99 | 0.060 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2005 | 7 | 0.060 |
Why?
|
| DNA Primers | 1 | 2005 | 300 | 0.060 |
Why?
|
| Staphylococcus aureus | 1 | 2006 | 180 | 0.060 |
Why?
|
| Interleukin-8 | 1 | 2005 | 95 | 0.050 |
Why?
|
| Mice, Inbred C3H | 1 | 2004 | 173 | 0.050 |
Why?
|
| Time Factors | 4 | 2006 | 3748 | 0.050 |
Why?
|
| Flow Cytometry | 3 | 2002 | 662 | 0.050 |
Why?
|
| Alginates | 1 | 2004 | 50 | 0.050 |
Why?
|
| Macrophages | 1 | 1989 | 1035 | 0.050 |
Why?
|
| Saliva | 1 | 2024 | 100 | 0.050 |
Why?
|
| HIV Seropositivity | 2 | 1995 | 81 | 0.050 |
Why?
|
| Drug Design | 2 | 2021 | 137 | 0.050 |
Why?
|
| Pneumonia, Bacterial | 1 | 2004 | 90 | 0.050 |
Why?
|
| Adult | 7 | 2024 | 17251 | 0.050 |
Why?
|
| Nucleocapsid Proteins | 1 | 2023 | 33 | 0.050 |
Why?
|
| Seroepidemiologic Studies | 1 | 2023 | 51 | 0.050 |
Why?
|
| Dogs | 1 | 2024 | 315 | 0.050 |
Why?
|
| Propidium | 1 | 2022 | 3 | 0.050 |
Why?
|
| Agglutination | 1 | 2022 | 4 | 0.050 |
Why?
|
| Immune Sera | 1 | 2022 | 35 | 0.050 |
Why?
|
| Pregnancy Complications, Infectious | 3 | 2001 | 70 | 0.050 |
Why?
|
| Lipopolysaccharides | 1 | 2025 | 623 | 0.050 |
Why?
|
| Precipitin Tests | 2 | 1999 | 77 | 0.040 |
Why?
|
| Transfection | 1 | 2003 | 701 | 0.040 |
Why?
|
| Neoplasm Proteins | 2 | 2005 | 285 | 0.040 |
Why?
|
| Biomarkers, Tumor | 1 | 2005 | 521 | 0.040 |
Why?
|
| Cross Protection | 1 | 2021 | 6 | 0.040 |
Why?
|
| Protein Precursors | 2 | 1993 | 85 | 0.040 |
Why?
|
| Fimbriae Proteins | 1 | 2021 | 13 | 0.040 |
Why?
|
| Gastric Acid | 1 | 2021 | 9 | 0.040 |
Why?
|
| Mass Spectrometry | 1 | 2022 | 295 | 0.040 |
Why?
|
| Receptors, Chemokine | 1 | 2000 | 30 | 0.040 |
Why?
|
| Plants, Genetically Modified | 1 | 2021 | 23 | 0.040 |
Why?
|
| Silicon | 1 | 2020 | 17 | 0.040 |
Why?
|
| Porosity | 1 | 2020 | 41 | 0.040 |
Why?
|
| Gelatin | 1 | 2020 | 29 | 0.040 |
Why?
|
| Vero Cells | 1 | 2020 | 81 | 0.040 |
Why?
|
| Immunoconjugates | 1 | 2021 | 95 | 0.040 |
Why?
|
| Bacterial Adhesion | 1 | 2021 | 65 | 0.040 |
Why?
|
| Solubility | 1 | 2020 | 191 | 0.040 |
Why?
|
| Phylogeny | 1 | 2021 | 386 | 0.040 |
Why?
|
| Mutation, Missense | 1 | 2021 | 190 | 0.040 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2020 | 86 | 0.040 |
Why?
|
| Aotidae | 1 | 2020 | 11 | 0.040 |
Why?
|
| Intestine, Small | 1 | 2020 | 82 | 0.040 |
Why?
|
| Phosphates | 1 | 2020 | 103 | 0.040 |
Why?
|
| Complement System Proteins | 2 | 1998 | 110 | 0.040 |
Why?
|
| Transformation, Genetic | 1 | 1999 | 31 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2023 | 1159 | 0.040 |
Why?
|
| Antibodies, Blocking | 1 | 1999 | 39 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2010 | 3137 | 0.040 |
Why?
|
| Genotype | 1 | 2021 | 657 | 0.040 |
Why?
|
| Binding, Competitive | 3 | 1994 | 96 | 0.040 |
Why?
|
| Lung | 1 | 2004 | 962 | 0.040 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2020 | 463 | 0.040 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1999 | 364 | 0.040 |
Why?
|
| Middle Aged | 5 | 2024 | 18156 | 0.040 |
Why?
|
| Drug Stability | 1 | 2019 | 144 | 0.040 |
Why?
|
| Polysaccharides | 1 | 2000 | 153 | 0.040 |
Why?
|
| Epithelial Cells | 1 | 2021 | 410 | 0.040 |
Why?
|
| Drug Compounding | 1 | 2019 | 79 | 0.040 |
Why?
|
| Receptors, Cytokine | 1 | 1998 | 13 | 0.040 |
Why?
|
| Thrombopoietin | 1 | 1998 | 11 | 0.040 |
Why?
|
| Megakaryocytes | 1 | 1998 | 18 | 0.040 |
Why?
|
| Immunoglobulin Light Chains | 1 | 1998 | 16 | 0.040 |
Why?
|
| Vaccination | 1 | 2001 | 374 | 0.040 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 2 | 1990 | 110 | 0.040 |
Why?
|
| Reassortant Viruses | 1 | 1998 | 10 | 0.030 |
Why?
|
| Massachusetts | 1 | 2024 | 2130 | 0.030 |
Why?
|
| Hematopoiesis | 1 | 1998 | 127 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2020 | 615 | 0.030 |
Why?
|
| Multiple Myeloma | 1 | 2003 | 367 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2006 | 2473 | 0.030 |
Why?
|
| Chimera | 3 | 2003 | 44 | 0.030 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 2 | 2009 | 281 | 0.030 |
Why?
|
| Spleen | 2 | 1990 | 474 | 0.030 |
Why?
|
| Cinnamates | 1 | 1996 | 9 | 0.030 |
Why?
|
| Antimetabolites | 1 | 1996 | 18 | 0.030 |
Why?
|
| Ganciclovir | 1 | 1996 | 18 | 0.030 |
Why?
|
| Recurrence | 2 | 2006 | 654 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 1 | 1998 | 343 | 0.030 |
Why?
|
| Ebola Vaccines | 1 | 2016 | 2 | 0.030 |
Why?
|
| Democratic Republic of the Congo | 1 | 2016 | 19 | 0.030 |
Why?
|
| Antigen-Antibody Complex | 1 | 2016 | 52 | 0.030 |
Why?
|
| Drug Synergism | 3 | 2001 | 141 | 0.030 |
Why?
|
| Burkitt Lymphoma | 1 | 1996 | 74 | 0.030 |
Why?
|
| Disease Outbreaks | 1 | 2016 | 110 | 0.030 |
Why?
|
| Tissue Donors | 1 | 2016 | 146 | 0.030 |
Why?
|
| Survivors | 1 | 2016 | 186 | 0.030 |
Why?
|
| Aged | 3 | 2024 | 14882 | 0.030 |
Why?
|
| Receptors, HIV | 1 | 1994 | 16 | 0.030 |
Why?
|
| ErbB Receptors | 2 | 2005 | 127 | 0.030 |
Why?
|
| Mutation | 2 | 2020 | 2656 | 0.030 |
Why?
|
| AIDS-Related Complex | 1 | 1993 | 3 | 0.030 |
Why?
|
| Viral Load | 2 | 2006 | 229 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 1993 | 101 | 0.030 |
Why?
|
| Administration, Topical | 1 | 2013 | 50 | 0.020 |
Why?
|
| Clone Cells | 2 | 1990 | 111 | 0.020 |
Why?
|
| Child | 1 | 2023 | 4554 | 0.020 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2013 | 29 | 0.020 |
Why?
|
| Vaccines, Synthetic | 1 | 1993 | 80 | 0.020 |
Why?
|
| G(M1) Ganglioside | 1 | 1992 | 12 | 0.020 |
Why?
|
| Radiation Chimera | 1 | 1992 | 61 | 0.020 |
Why?
|
| Lymphocytes | 1 | 1993 | 204 | 0.020 |
Why?
|
| Epidermal Growth Factor | 2 | 2005 | 49 | 0.020 |
Why?
|
| Kinetics | 2 | 1993 | 759 | 0.020 |
Why?
|
| Immunoglobulin M | 1 | 1992 | 116 | 0.020 |
Why?
|
| CD40 Ligand | 2 | 2005 | 158 | 0.020 |
Why?
|
| Pregnancy | 4 | 2001 | 2362 | 0.020 |
Why?
|
| Major Histocompatibility Complex | 1 | 1992 | 85 | 0.020 |
Why?
|
| Antigens, Protozoan | 2 | 1989 | 63 | 0.020 |
Why?
|
| SAIDS Vaccines | 1 | 2011 | 21 | 0.020 |
Why?
|
| Young Adult | 1 | 2021 | 4772 | 0.020 |
Why?
|
| Immunohistochemistry | 2 | 2006 | 895 | 0.020 |
Why?
|
| Vagina | 1 | 2011 | 87 | 0.020 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 1992 | 183 | 0.020 |
Why?
|
| CD8 Antigens | 1 | 1990 | 53 | 0.020 |
Why?
|
| DNA | 2 | 1992 | 856 | 0.020 |
Why?
|
| Immunoassay | 1 | 2010 | 71 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 1992 | 752 | 0.020 |
Why?
|
| Superoxides | 1 | 1989 | 73 | 0.020 |
Why?
|
| Luminescent Measurements | 1 | 1989 | 40 | 0.020 |
Why?
|
| Hydrogen Peroxide | 1 | 1989 | 83 | 0.020 |
Why?
|
| Pilot Projects | 2 | 2005 | 1008 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 1989 | 185 | 0.020 |
Why?
|
| Erythrocytes | 1 | 1990 | 146 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 1993 | 636 | 0.020 |
Why?
|
| Plasmodium yoelii | 1 | 1989 | 6 | 0.020 |
Why?
|
| Immunotherapy, Adoptive | 1 | 1990 | 100 | 0.020 |
Why?
|
| Genetic Therapy | 1 | 1996 | 832 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 1989 | 324 | 0.020 |
Why?
|
| Cell Survival | 1 | 1990 | 586 | 0.020 |
Why?
|
| Alanine | 1 | 2008 | 48 | 0.020 |
Why?
|
| Cytokines | 2 | 2005 | 950 | 0.020 |
Why?
|
| Anti-Infective Agents | 1 | 2010 | 151 | 0.020 |
Why?
|
| Amino Acid Motifs | 1 | 2008 | 156 | 0.020 |
Why?
|
| Synchrotrons | 1 | 2007 | 4 | 0.020 |
Why?
|
| Asparagine | 1 | 2007 | 25 | 0.020 |
Why?
|
| Gene Transfer Techniques | 1 | 2010 | 324 | 0.020 |
Why?
|
| Hydrogen Bonding | 1 | 2007 | 128 | 0.020 |
Why?
|
| Models, Chemical | 1 | 2007 | 137 | 0.020 |
Why?
|
| Desmogleins | 1 | 2006 | 2 | 0.020 |
Why?
|
| Protein Structure, Secondary | 1 | 2007 | 260 | 0.020 |
Why?
|
| Infant, Newborn | 2 | 2001 | 1410 | 0.020 |
Why?
|
| Lymphocyte Count | 1 | 2006 | 71 | 0.020 |
Why?
|
| Virulence | 1 | 2007 | 199 | 0.020 |
Why?
|
| Viremia | 1 | 2006 | 46 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2006 | 58 | 0.020 |
Why?
|
| Remission Induction | 1 | 2006 | 148 | 0.020 |
Why?
|
| Intradermal Tests | 1 | 2006 | 3 | 0.020 |
Why?
|
| Acantholysis | 1 | 2006 | 5 | 0.020 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2006 | 37 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2007 | 491 | 0.020 |
Why?
|
| Rituximab | 1 | 2006 | 88 | 0.020 |
Why?
|
| Complement C3 | 1 | 2006 | 60 | 0.010 |
Why?
|
| Crystallography | 1 | 2005 | 26 | 0.010 |
Why?
|
| Mice, Nude | 1 | 1986 | 287 | 0.010 |
Why?
|
| Antibodies | 1 | 1986 | 187 | 0.010 |
Why?
|
| Prostaglandins | 1 | 2005 | 18 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2006 | 460 | 0.010 |
Why?
|
| Fas Ligand Protein | 1 | 2005 | 40 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2006 | 576 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2007 | 482 | 0.010 |
Why?
|
| Staphylococcal Infections | 1 | 2006 | 130 | 0.010 |
Why?
|
| Cell Communication | 1 | 2005 | 133 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2005 | 540 | 0.010 |
Why?
|
| Africa | 1 | 2003 | 29 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2005 | 234 | 0.010 |
Why?
|
| Human Immunodeficiency Virus Proteins | 1 | 2002 | 6 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2005 | 959 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2005 | 372 | 0.010 |
Why?
|
| Viral Regulatory and Accessory Proteins | 1 | 2002 | 21 | 0.010 |
Why?
|
| Immunity, Maternally-Acquired | 1 | 2001 | 11 | 0.010 |
Why?
|
| Virus Shedding | 1 | 2001 | 17 | 0.010 |
Why?
|
| Macaca | 1 | 2001 | 30 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2003 | 389 | 0.010 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2001 | 32 | 0.010 |
Why?
|
| Virus Assembly | 1 | 2001 | 54 | 0.010 |
Why?
|
| Delivery, Obstetric | 1 | 2001 | 55 | 0.010 |
Why?
|
| Lactation | 1 | 2001 | 77 | 0.010 |
Why?
|
| Receptors, CXCR4 | 1 | 2000 | 43 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2005 | 1564 | 0.010 |
Why?
|
| Receptors, CCR5 | 1 | 2000 | 59 | 0.010 |
Why?
|
| Cesarean Section | 1 | 2001 | 100 | 0.010 |
Why?
|
| Apoptosis | 1 | 2005 | 1099 | 0.010 |
Why?
|
| Transforming Growth Factor alpha | 1 | 1999 | 15 | 0.010 |
Why?
|
| Postpartum Period | 1 | 2001 | 188 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 1999 | 194 | 0.010 |
Why?
|
| Receptors, Thrombopoietin | 1 | 1998 | 4 | 0.010 |
Why?
|
| Colony-Forming Units Assay | 1 | 1998 | 26 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 1998 | 97 | 0.010 |
Why?
|
| Cell Division | 1 | 1999 | 449 | 0.010 |
Why?
|
| Bone Marrow | 1 | 1998 | 176 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1999 | 853 | 0.010 |
Why?
|
| Hygromycin B | 1 | 1996 | 2 | 0.010 |
Why?
|
| Thymidine Kinase | 1 | 1996 | 18 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 1999 | 431 | 0.010 |
Why?
|
| Epstein-Barr Virus Nuclear Antigens | 1 | 1996 | 19 | 0.010 |
Why?
|
| Simplexvirus | 1 | 1996 | 26 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 1996 | 168 | 0.010 |
Why?
|
| Metabolic Clearance Rate | 1 | 1996 | 49 | 0.010 |
Why?
|
| Half-Life | 1 | 1996 | 81 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 1996 | 174 | 0.010 |
Why?
|
| Adolescent | 1 | 2006 | 6247 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2003 | 3297 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 1996 | 686 | 0.010 |
Why?
|
| HIV Envelope Protein gp160 | 1 | 1993 | 4 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 1995 | 601 | 0.010 |
Why?
|
| Vaccinia virus | 1 | 1993 | 69 | 0.010 |
Why?
|
| Membrane Fusion | 1 | 1993 | 67 | 0.010 |
Why?
|
| Immunoglobulin Idiotypes | 1 | 1992 | 5 | 0.010 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 1992 | 9 | 0.010 |
Why?
|
| Gene Rearrangement | 1 | 1992 | 41 | 0.010 |
Why?
|
| Biomarkers | 1 | 1995 | 1469 | 0.000 |
Why?
|
| Transcription Factors | 1 | 1996 | 1550 | 0.000 |
Why?
|